Paraneoplastic syndromes are often a diagnostic challenge to doctors and may have a heterogeneous presentation, including humoral hypercalcemia of malignancy (HHM), most commonly caused by squamous cell cancer and renal, ovarian, endometrial, and breast cancer. Chronic inflammatory demyelinating polyneuropathy (CIDP) has been described in patients affected by several types of cancer, especially hematologic malignancies, and a possible paraneoplastic pathogenesis of this neurological disease has been suggested. This report describes a 56-year-old man with a history of CIDP diagnosed 3 months earlier and persistently elevated aminotransferases for 18 months who was admitted to our internal medicine unit with abdominal pain, fatigue, and severe hypercalcemia with low serum intact parathyroid hormone. Parathyroid hormone-related protein (PTH-rP) was markedly high. Liver imaging showed a large hepatic mass in the right lobe, and percutaneous ultrasound-guided biopsy revealed histopathological findings consistent with a combined hepatocholangiocarcinoma (CHCC). We supposed that both HHM and CIDP could represent a paraneoplastic manifestation of CHCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612990 | PMC |
| http://dx.doi.org/10.1155/2019/3418950 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MRI features of combined hepatocellular-cholangiocarcinoma.
Abdom Radiol (NY)
January 2025
Department of Radiology, Lahey Hospital and Medical Center, Burlington, MA, USA.
Article Synopsis
- Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare and aggressive liver tumor with a worse prognosis compared to hepatocellular carcinoma (HCC) and similar to intrahepatic cholangiocarcinoma (iCCA).
- There is limited MRI literature regarding cHCC-CCA, making it a challenging diagnosis; however, specific imaging patterns can help distinguish it from other liver tumors.
- Tumor markers might be useful for identification, and sampling challenges arise due to intratumoral heterogeneity, which can lead to misdiagnosis if biopsies don't capture both histologic components.
Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching.
Surgery
February 2024
Department of Digestive and Hepato-pancreatic-biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Paris Est Créteil University, UPEC, France; Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Créteil, France. Electronic address:
Article Synopsis
- Combined hepatocholangiocarcinoma is a rare and aggressive type of cancer combining features of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma, leading to a poor prognosis.
- A multicenter international study analyzed the surgery outcomes for patients with combined hepatocholangiocarcinoma and compared them with those having either hepatocellular carcinoma or intrahepatic cholangiocarcinoma from 2000 to 2021.
- The results showed significant differences in overall survival rates at 1, 3, and 5 years among the groups, with combined hepatocholangiocarcinoma having the lowest survival rates, while disease-free survival rates were similar across groups, suggesting that combined hepatochol
An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma.
JHEP Rep
June 2023
Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Background & Aims: Management of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is not well-defined. Therefore, we evaluated the management of cHCC-CCA using an online hospital-wide multicentre survey sent to expert centres.
Methods: A survey was sent to members of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and the International Cholangiocarcinoma Research Network (ICRN), in July 2021.
MALDI Imaging, a Powerful Multiplex Approach to Decipher Intratumoral Heterogeneity: Combined Hepato-Cholangiocarcinomas as Proof of Concept.
Cancers (Basel)
April 2023
Centre de Recherche sur L'inflammation, Inserm, Université Paris Cité, F-75018 Paris, France.
Combined hepato-cholangiocarcinomas (cHCC-CCA) belong to the spectrum of primary liver carcinomas, which include hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinomas (iCCA) at both ends of the spectrum. Mainly due to the high intratumor heterogeneity of cHCC-CCA, its diagnosis and pathological description remain challenging. Taking advantage of in situ non-targeted molecular mapping provided by MALDI (Matrix Assisted Laser Desorption Ionization) imaging, we sought to develop a multiscale and multiparametric morphological approach, integrating molecular and conventional pathological analysis.
View Article and Find Full Text PDFNew insights into the pathophysiology and clinical care of rare primary liver cancers.
JHEP Rep
February 2021
Service d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
Hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic haemangioendothelioma and hepatic angiosarcoma represent less than 5% of primary liver cancers. Fibrolamellar carcinoma and hepatic haemangioendothelioma are driven by unique somatic genetic alterations ( and fusions, respectively), while the pathogenesis of hepatocholangiocarcinoma remains more complex, as suggested by its histological diversity. Histology is the gold standard for diagnosis, which remains challenging even in an expert centre because of the low incidences of these liver cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!